Robert B. Jones - 20 Nov 2023 Form 4 Insider Report for ACURA PHARMACEUTICALS, INC

Role
President & CEO
Signature
/s/ Robert B. Jones
Issuer symbol
N/A
Transactions as of
20 Nov 2023
Net transactions value
$0
Form type
4
Filing time
20 Nov 2023, 12:08:01 UTC
Previous filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACUR Common Stock Options Exercise +40,000 +6.6% 643,555 20 Nov 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACUR Restricted Stock Unit (2021 Plan) Options Exercise -40,000 -100% 0 20 Nov 2023 Common Stock 40,000 $0.0100 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents exchange of restricted stock units.
F2 Par value of $.01 was paid by Reporting Person upon exchange of Restricted Stock Units for stock.
F3 Not Applicable.
F4 40,000 Restricted Stock Units were granted on March 16, 2022 and were 100% vested on December 31, 2022